OmniAb (OABI) Cash from Operations (2021 - 2026)
OmniAb (OABI) reported Cash from Operations of 4914000.0 for Q1 2026, up 69.04% year-over-year from 2907007.38 in Q1 2025, and up 13.39% quarter-over-quarter from 5674000.0 in Q4 2025.
OmniAb (OABI) Cash from Operations (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Cash from Operations data on file, last reported at 4914000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 4914000.0, up 69.04% year-over-year; the trailing twelve-month figure through Mar 2026 was 25497000.0 (up 33.78% YoY), and the FY2025 annual result was 36455000.0, up 8.09% from the prior year.
- Cash from Operations grew to 4914000.0 in Q1 2026 per OABI's latest filing, from 5674000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 27688000.0 in Q1 2023 and troughed at 17032000.0 in Q1 2024.
- A 5-year average of 4839588.24 and a median of 6198000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations slumped 337.92% in 2022, then jumped 137.87% in 2023.
- A 5-year view of Cash from Operations shows it stood at 7143000.0 in 2022, then retreated by 27.69% to 9121000.0 in 2023, then soared by 57.55% to 3872000.0 in 2024, then plunged by 46.54% to 5674000.0 in 2025, then rose by 13.39% to 4914000.0 in 2026.
- Business Quant data shows OABI's Cash from Operations at 4914000.0 in Q1 2026, 5674000.0 in Q4 2025, and 9763000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | -4.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.91 Mn |
| Mar 31, 2026 | -4.91 Mn |
| Dec 31, 2025 | -5.67 Mn |
| Dec 31, 2025 | -5.67 Mn |
| Sep 30, 2025 | -9.76 Mn |
| Sep 30, 2025 | -9.76 Mn |
| Jun 30, 2025 | -5.15 Mn |
| Jun 30, 2025 | -5.15 Mn |
| Mar 31, 2025 | -15.87 Mn |
| Mar 31, 2025 | -15.87 Mn |
| Dec 31, 2024 | -3.87 Mn |
| Dec 31, 2024 | -3.87 Mn |
| Sep 30, 2024 | -6.58 Mn |
| Sep 30, 2024 | -6.58 Mn |
| Jun 30, 2024 | -12.18 Mn |
| Jun 30, 2024 | -12.18 Mn |
| Mar 31, 2024 | -17.03 Mn |
| Mar 31, 2024 | -17.03 Mn |
| Dec 31, 2023 | -9.12 Mn |
| Dec 31, 2023 | -9.12 Mn |